Trial Profile
Randomized Study of Intravenous Calaspargase Pegol (SC-PEG Asparaginase) and Intravenous Oncaspar in Children and Adolescents With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 01 Oct 2022
Price :
$35
*
At a glance
- Drugs Calaspargase pegol (Primary) ; Pegaspargase
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Pharmacokinetics
- 14 Dec 2021 Results from trials (DFCI 05-001) or (DFCI 11-001) assessing impact of Age, Body Surface Area, and Body Mass Index on Pegaspargase Toxicity and Pharmacokinetics presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 06 Jul 2021 Results assessing efficacy and toxicity of calaspargase compared with pegaspargase in children and adolescents with newly diagnosed ALL and LL during induction and postinduction treatment phases, published in the Journal of Clinical Oncology.
- 20 Oct 2020 Planned End Date changed from 1 Jul 2021 to 1 Jul 2025.